BioMark Diagnostics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022
For the nine months, sales was CAD 0.113746 million compared to CAD 0.019818 million a year ago. Net loss was CAD 1.34 million compared to CAD 0.724031 million a year ago. Basic loss per share from continuing operations was CAD 0.02 compared to CAD 0.01 a year ago.